An apparatus for producing a radiolabeled compound is a production apparatus which produces a radiolabeled compound by introducing a radioisotope into a non-radioactive labeling precursor compound. The production apparatus includes a solid phase extraction unit in which a specific process which is a reaction of an intermediate compound, a purification of the intermediate compound, or a purification of the radiolabeled compound is carried out; and a cooling unit that cools the solid phase extraction unit, when the specific process is carried out.

An apparatus for producing a radiolabeled compound is a production apparatus which produces a radiolabeled compound by introducing a radioisotope into a non-radioactive labeling precursor compound. The production apparatus includes a solid phase extraction unit in which a specific process which is a reaction of an intermediate compound, a purification of the intermediate compound, or a purification of the radiolabeled compound is carried out; and a cooling unit that cools the solid phase extraction unit, when the specific process is carried out.

The present invention relates to a novel composition comprising 1-amino-3-[.sup.18F]-fluorocyclobutanecarboxylic acid ([.sup.18F]-FACBC) wherein said composition has certain superior properties in comparison with known compositions comprising [.sup.18F]-FACBC. Also provided by the invention is a method to obtain said composition.

The present invention relates to a novel composition comprising 1-amino-3-[.sup.18F]-fluorocyclobutanecarboxylic acid ([.sup.18F]-FACBC) wherein said composition has certain superior properties in comparison with known compositions comprising [.sup.18F]-FACBC. Also provided by the invention is a method to obtain said composition.

Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.

It is an object of the present invention to provide an excellent method for producing an excellent therapeutic agent.

The solution of the present invention is as shown in the following scheme:

##STR00001## wherein R.sup.1 represents a C1-C6 alkyl group, R.sup.2 represents a C1-C6 alkyl group, and R.sup.3 represents a C1-C6 alkyl group.

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Cyclic vinylogous amides of Formula I are disclosed

##STR00001##

The compounds are useful for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine. The compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.

Cyclic vinylogous amides of Formula I are disclosed

##STR00001##

The compounds are useful for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine. The compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.